Friday 6 November 2026
Export IDXX’s income statement to Excel — free account
IDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +9.86%
- EPS
- +17.3%
- Free cash flow
- +17.6%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
677.29
6.58
+0.98%
Follow IDXX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
9 | 9 | 8 | 8 |
+8 more TTM periods Free account |
| 68.93% | 74.21% | 72.92% | 66.20% | ||
| 33.33% | 33.65% | 33.19% | 31.89% | ||
ROIC |
46.00% | 48.87% | 48.68% | 45.33% | |
Return on Tangible Assets |
122.14% | 119.33% | 122.43% | 104.65% | |
Average Days of Receivables |
48.21 | 50.27 | 49.55 | 46.85 | |
Free Cash Flow per Share |
16.49 | 15.67 | 13.28 | 11.89 | |
Free Cash Flow |
1,300.00 | 1,237.09 | 1,058.11 | 956.58 | |
Capital Expenditures |
(118.89) | (134.42) | (151.98) | (225.23) | |
| Other line items | |||||
Cash ROIC |
53.24% | 54.75% | 47.95% | 42.79% | |
Accounts Receivable Turnover |
7.88 | 7.67 | 7.86 | 8.39 | |
Accounts Payable Turnover |
12.58 | 13.92 | 13.49 | 14.64 | |
Inventory Turnover |
4.44 | 4.36 | 4.34 | 4.33 | |
Average Days of Payables |
32.36 | 27.56 | 28.12 | 24.51 | |
Days of Inventory on Hand |
82.09 | 83.59 | 82.73 | 83.86 | |
Tax Rate |
(0.20) | (0.20) | (0.20) | (0.20) | |
Research and Development Expense of Revenue |
5.72% | 5.74% | 5.80% | 5.84% | |
Selling, General and Administrative Expense of Revenue |
24.69% | 24.67% | 24.63% | 24.36% | |
Share Based Compensation of Revenue |
1.39% | 1.38% | 1.39% | 1.39% | |
Interest Coverage |
43.54 | 38.60 | 36.12 | 35.01 | |
Operating CF/Net income |
1.20 | 1.20 | 1.10 | 1.12 | |
Depreciation/Fixed assets |
0.22 | 0.21 | 0.20 | 0.19 | |
Capex/Depreciation |
(0.75) | (0.87) | (1.02) | (1.55) | |
Revenue per Share |
59.15 | 57.67 | 55.82 | 53.51 | |
Operating CF per Share |
18.00 | 17.37 | 15.19 | 14.69 | |
Capex per Share |
(1.51) | (1.70) | (1.91) | (2.80) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026